QIAGEN N.V.
QIAGEN develops Sample to Insight solutions that transform biological samples into molecular insights. Its offerings include consumables, instrumentation, molecular testing instruments and digital solutions, including QuantiFERON tests for tuberculosis testing and the AmniSure ROM test for detecting amniotic fluid. The company sells consumables and instrumentation products through distributors, including in certain international markets. Its products support diagnostic testing and other molecular testing activities. QIAGEN is headquartered at its principal executive office at Hulsterweg 82, 5912 PL Venlo, The Netherlands.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $QGEN in the last 30 days.
See all $QGEN insider activity →Evercore ISI raised BlackRock's (BLK) price target to $1,315, maintaining an Outperform rating. BlackRock disclosed stakes in QIAGEN (11.87% indirect, 13.18% voting rights) and Copasa (5%).
JPMorgan Chase & Co. held 5.05% of QIAGEN N.V.'s capital and voting rights as of October 30, 2026, according to an AFM notification. The stake includes 1.81% indirect real and 3.24% indirect potential interest. This is an ownership disclosure and not a change in QIAGEN's operations or financial results.
Massachusetts Financial Services Company held 3.44% of QIAGEN N.V.'s voting rights and 2.82% of its capital interest as of October 29, 2026, according to the AFM. This is an ownership disclosure, not a change in QIAGEN's operating outlook or financial results.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning QGEN (QIAGEN N.V.). Coverage has skewed bullish: 4 bullish, 7 neutral, and 0 bearish.
Recent QGEN coverage spans financial news, regulation and earnings.
Share price may rise on perceived validation from a major investor.
JPMorgan Chase & Co. held 5.05% of QIAGEN N.V.'s capital and voting rights as of October 30, 2026, according to an AFM notification. The stake includes 1.81% indirect real and 3.24% indirect potential interest. This is an ownership disclosure and not a change in QIAGEN's operations or financial results.
Massachusetts Financial Services Company held 3.44% of QIAGEN N.V.'s voting rights and 2.82% of its capital interest as of October 29, 2026, according to the AFM. This is an ownership disclosure, not a change in QIAGEN's operating outlook or financial results.
Bank of America reported a 5.11% stake in QIAGEN N.V. as of November 2, 2026, according to an AFM disclosure. No prior holding data was provided for comparison.
QIAGEN N.V. disclosed that BlackRock holds 11.87% capital interest and 13.18% voting rights in the company, according to an AFM filing. No prior-period comparison was provided. The disclosure is a regulatory ownership update, not an earnings or operating report.
AlphAI scores every news story that mentions QGEN with an AI model for sentiment and relevance, and aggregates insider trades from QIAGEN N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evercore ISI raised BlackRock's (BLK) price target to $1,315, maintaining an Outperform rating. BlackRock disclosed stakes in QIAGEN (11.87% indirect, 13.18% voting rights) and Copasa (5%).
JPMorgan Chase & Co. held 5.05% of QIAGEN N.V.'s capital and voting rights as of October 30, 2026, according to an AFM notification. The stake includes 1.81% indirect real and 3.24% indirect potential interest. This is an ownership disclosure and not a change in QIAGEN's operations or financial results.
Massachusetts Financial Services Company held 3.44% of QIAGEN N.V.'s voting rights and 2.82% of its capital interest as of October 29, 2026, according to the AFM. This is an ownership disclosure, not a change in QIAGEN's operating outlook or financial results.
Bank of America reported a 5.11% stake in QIAGEN N.V. as of November 2, 2026, according to an AFM disclosure. No prior holding data was provided for comparison.
QIAGEN N.V. disclosed that BlackRock holds 11.87% capital interest and 13.18% voting rights in the company, according to an AFM filing. No prior-period comparison was provided. The disclosure is a regulatory ownership update, not an earnings or operating report.
T. Rowe Price Group reported a 4.51% stake in QIAGEN N.V. (QIA) according to a regulatory filing. The disclosure did not provide a prior-period comparison for context.
Barclays held 4.59% of QIAGEN's capital and voting rights as of November 2, according to an AFM notification. The stake includes 0.05% indirect real and 4.53% indirect potential. This is a regulatory disclosure, not an operational change.
UBS Group AG reported a 5.62% stake in QIAGEN N.V. as of October 30, 2026, according to an AFM notification. No prior-period comparison was provided.
QIAGEN N.V. shareholders approved CEO Jonathan M. Pratt as a Managing Director and board member. Pratt became CEO on September 1, 2026, according to the company.
QIAGEN N.V. announced the filing of its Form 6-K report for Q3 2026 with the SEC, available on its website. The company is listed on multiple exchanges, including NYSE and SIX.
